Urogenit Tract Infect.  2016 Aug;11(2):43-48. 10.14777/uti.2016.11.2.43.

Antibiotic Resistance and Novel Antibiotics for the Treatment of Urinary Tract Infections

• Wagenlehner F

• KMID: 2350755
• DOI: http://doi.org/10.14777/uti.2016.11.2.43

Abstract

Surveillance data on antibiotic resistance need to be considered with respect to the origin of isolates, types of surveillance studies, and types of types of registered infections. Antibiotic resistance in gram-negative uropathogens has been investigated in both local and multinational studies. A compilation of worldwide studies for example showed resistance rates of gram-negative uropathogens against fluoroquinolones in 10% to 80%, against cephalosporines in 5% to 70% and against carbapenems in 0% to 35%. A specific surveillance study in the field of urology"”the global prevalence of infections in urology (GPIU) study"”is a point prevalence study with a global effort to create surveillance data in patients at various urological departments with health-care associated urogenital infections (HAUTIs). The GPIU study has been performed annually since 2003, with a total inclusion of 27,542 patients, thus far. Resistance rates of most uropathogens against all tested antibiotics were high, especially with multidrug resistance. A concerning finding was that the severity of HAUTI is also increasing"”25% being urosepsis in recent years. In order to keep up with this alarming trend, novel antibiotics for the treatment of urinary tract infections need to be developed. Several strategies are currently employed: Beta-lactam/beta-lactamase inhibitor combinations are extended to cephalosporines and carbapenems. Novel fluroroquinolones have been developed, and so called siderophore antibiotics are being tested. Novel aminoglycosides and novel tetracyclines are also in the clinical development phases. Thus, several antibiotic substances are currently being developed, or in the late clinical phases of development.

Keyword

Urinary tract infections; Surveillance studies; Drug resistance, microbial; Novel antibiotics

MeSH Terms

Aminoglycosides
Anti-Bacterial Agents*
Carbapenems
Cross-Sectional Studies
Drug Resistance, Microbial*
Drug Resistance, Multiple
Fluoroquinolones
Humans
Prevalence
Tetracyclines
Urinary Tract Infections*
Urinary Tract*
Urology
Aminoglycosides
Anti-Bacterial Agents
Carbapenems
Fluoroquinolones
Tetracyclines

Reference

1.Magill SS., Edwards JR., Bamberg W., Beldavs ZG., Dumyati G., Kainer MA, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014. 370:1198–208.

2.Johansen TE. Nosocomially acquired urinary tract infections in urology departments. Why an international prevalence study is needed in urology. Int J Antimicrob Agents. 2004. 23(Suppl 1):S30–4.

3.Bjerklund Johansen TE., Cek M., Naber K., Stratchounski L., Svendsen MV., Tenke P. PEP and PEAP study investigators; European Society of Infections in Urology. Prevalence of hospital-acquired urinary tract infections in urology departments. Eur Urol. 2007. 51:1100–11. discussion 1112.

4.Zowawi HM., Harris PN., Roberts MJ., Tambyah PA., Schembri MA., Pezzani MD, et al. The emerging threat of multidrug-resistant Gram-negative bacteria in urology. Nat Rev Urol. 2015. 12:570–84.

5.Wagenlehner F., Tandogdu Z., Bartoletti R., Cai T., Cek M., Kulchavenya E, et al. The global prevalence of infections in urology study: a long-term, worldwide surveillance study on urological infections. Pathogens. 2016. 5.

6.Tandoğdu Z., Bartoletti R., Cai T., Cek M., Grabe M., Kulchavenya E, et al. Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003-2013. World J Urol. 2016. 34:1193–200.

7.Tandogdu Z., Cek M., Wagenlehner F., Naber K., Tenke P., van Ostrum E, et al. Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the global prevalence of infections in urology study. World J Urol. 2014. 32:791–801.

8.Wagenlehner FM., Alidjanov JF. Efficacy, pharmacokinetic and pharmacodynamic profile of ceftolozane+tazobactam in the treatment of complicated urinary tract infections. Expert Opin Drug Metab Toxicol. 2016. 12:959–66.

9.Wagenlehner FM., Umeh O., Steenbergen J., Yuan G., Darouiche RO. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015. 385:1949–56.

10.Wagenlehner FM., Umeh O., Darouiche RO. Ceftolozane-tazobactam versus levofloxacin in urinary tract infection: authors' reply. Lancet. 2015. 386:1242.

11.Wagenlehner FM., Sobel JD., Newell P., Armstrong J., Huang X., Stone GG, et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis. 2016 Jun 16. [Epub].DOI: doi: 10.1093/cid/ciw378.

12.Carmeli Y., Armstrong J., Laud PJ., Newell P., Stone G., Wardman A, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016. 16:661–73.

13.Wagenlehner FM., Naber KG. Studying ceftazidime-avibactam in selected populations. Lancet Infect Dis. 2016. 16:621–3.

14.ClinicalTrials.gov. Efficacy and safety of imipenem+cilastatin/relebactam (MK-7655A) versus colistimethate sodium+ imipenem+cilastatin in imipenem-resistant bacterial infection (MK-7655A-013) (RESTORE-IMI 1) [Internet]. ClinicalTrials.gov;2016. [cited 2016 Aug 22]. Available from:. https://clinicaltrials.gov/ct2/show/NCT02452047.

15.Straubinger M., Blenk H., Naber KG., Wagenlehner FM. Urinary concentrations and antibacterial activity of BAL30072, a novel siderophore monosulfactam, against uropathogens after intravenous administration in healthy subjects. Antimicrob Agents Chemother. 2016. 60:3309–15.

16.Wagenlehner FM., Wagenlehner CM., Blenk B., Blenk H., Schubert S., Dalhoff A, et al. Urinary pharmacokinetics and bactericidal activity of finafloxacin (200 and 800 mg) in healthy volunteers receiving a single oral dose. Chemotherapy. 2011. 57:97–107.

17.Wagenlehner MNF., Bentley C., Lückermann M., Wohlert S., Fischer C., Vente A, et al. Safety and efficacy of finafloxacin versus ciprofloxacin (CPX) in the treatment of hospitalized patients with complicated urinary tract infections (cUTI) and pyelonephritis (PN) determined in a phase 2 clinical study. Proceedings of 55th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Diego:. 2015.

18.Livermore DM., Mushtaq S., Warner M., Zhang JC., Maharjan S., Doumith M, et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother. 2011. 66:48–53.

19.Riddle EA. Plazomicin versus levofloxaicn in complicated urinary tract infectins or pyelonephritis. Proceedings of 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco:. 2012.